Epicrispr Reports First Clinical Evidence of Increased Lean Muscle Volume in Patients with FSHD Following Treatment with EPI-321

Epicrispr Reports First Clinical Evidence of Increased Lean Muscle Volume in Patients with FSHD Following Treatment with EPI-321

Single-Dose EPI-321 Demonstrated a Positive Safety Profile and Increased Lean Muscle Volume Across the First Three Evaluable Patients at Six Months

EPI-321 is the First Investigational Therapy Designed to Silence DUX4, the Genetic Driver of FSHD

Epicrispr Biotechnologies, a clinical-stage company pioneering epigenetic therapies, today announced new interim data from its ongoing open-label Phase 1/2 first-in-human study of EPI-321 in facioscapulohumeral muscular dystrophy (FSHD), demonstrating the first reported clinical evidence that a therapy increased muscle volume in patients with FSHD, potentially providing a disease modifying benefit.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626528684/en/ Image caption: MRI images of Lean Muscle Volume (LMV) change from baseline at 6 months for the predicted digital twin without treatment (left) and actual EPI-321 treated patient (right) 6-months post dosing. Images show LMV was predicted to decline due to natural FSHD disease progression (orange colored muscles), but LMV was observed to increase (green muscles) following EPI-321 treatment. Images are from one participant in the study, however the increase in LMV seen here was observed across all n=3 patients 6-months post dosing. Images from Springbok Analytics.